8-K: STAAR Surgical Urges Alcon Merger Approval

STAAR Surgical Company's Board unanimously recommends the $28.00 per share all-cash merger with Alcon, citing compelling value and significant standalone risks, while refuting Broadwood Partners' opposition.

Summary

• STAAR Surgical Company's Board of Directors unanimously recommends the proposed all-cash merger with Alcon Research, LLC for $28.00 per share.
• The Board believes this offer maximizes value for stockholders, providing certain and immediate cash value at a significant premium.
• The decision follows over a year of evaluating strategic alternatives and negotiating favorable terms, including a 45-day 'window shop' period which expired on September 19, 2025, without any superior proposals.
• STAAR faces sustained challenges as a standalone company, including slowing growth in China, macroeconomic uncertainty, increasing competition, a limited product offering (primarily EVO and EVO+ ICLs), and tariff risks.
• Management projections do not signal a return to historical growth rates or profitability for STAAR as a standalone entity, with 2026 Net Sales projected at $340 million (2% CAGR from 2023) and an expected net loss for FY2025.
• The filing refutes claims by Broadwood Partners, a minority stockholder, arguing their views are flawed and misleading, and that their proposed alternative would expose stockholders to significant risks without a control premium.
• Soleus Capital, STAAR's second-largest active stockholder (approximately 6% ownership), has informed the Board of its support for the merger.

Sentiment

Score: 8

Explanation: The filing strongly advocates for the merger, highlighting significant premiums and de-risking for shareholders, while presenting a bleak outlook for the company as a standalone entity. The tone is very positive about the merger and negative about the alternative.

Positives

• The $28.00 per share all-cash consideration provides compelling, certain, and immediate cash value to stockholders.
• The offer represents a 51% premium to STAAR's closing stock price of $18.49 on August 4, 2025, the day prior to the transaction announcement.
• The offer represents a 59% premium to STAAR's 90-day volume-weighted average price (VWAP) of $18.00 as of August 4, 2025.
• The offer represents a 47% premium to the median sell-side analyst price target of $19.00 per share as of just prior to the transaction announcement.
• The premium is approximately 2.0x the median premium paid of 26% in comparable U.S. cash-only MedTech deals over $500 million since 2015.
• Alcon's significantly larger resources, including a sales force of 3,900 (vs. STAAR's 215), R&D spend of $876 million (vs. $54 million), and sales/marketing spend of $2,553 million (vs. $108 million), are expected to accelerate EVO ICL adoption globally.
• The merger de-risks STAAR's standalone plan and addresses ongoing business headwinds.
• Favorable merger agreement terms include a 45-day 'window shop' provision with a nominal $14.5 million (1%) break-up fee for certain proposals received during that period, and a $43.4 million (3%) fee for proposals received thereafter.
• The agreement includes no 'naked no vote' fee and provides for Alcon regulatory commitments with a $72 million (5%) break-up fee payable by Alcon to STAAR in certain circumstances due to failure to receive regulatory approvals.
• Soleus Capital, STAAR's second-largest active stockholder (approximately 6% ownership), supports the merger and intends to vote in favor.

Negatives

• STAAR's Net Sales have declined over the last two years (FY23-FY25), with FY24 Net Sales at $313.9 million and a Net Loss of $(20.2) million.
• STAAR's 2Q25 Net Sales were down 55% year-over-year, and Net Income (Loss) was $(17) million compared to Net Income of $7 million in 2Q24.
• Management projections for 2026 ($340 million Net Sales) represent a significantly lower go-forward growth profile (2% CAGR from 2023) compared to historical rates.
• China Net Sales, representing 51% of FY24 Net Sales, are projected to decline year-over-year in FY2025E and are expected to be flat compared to 2024 by 2026, down significantly from 2023.
• China procedure volumes for EVO ICLs were positive year-over-year in 1Q25, softened in 2Q25, and have not improved so far in 3Q25.
• STAAR is a single-product company, deriving nearly all Net Sales from EVO and EVO+ ICLs, which creates a heightened risk profile.
• The company has historically been unable to penetrate the market beyond high myopia patients, despite EVO ICLs being suitable for low, moderate, and high myopia.
• Increasing competition in China from new entrants and the potential for volume-based procurement (VBP) could drive downward pricing pressure.
• If the merger is not consummated, STAAR's stock price may decline significantly, exposing stockholders to substantial risk.
• Ongoing risks related to standalone prospects include the potential for creeping control by a single minority stockholder (Broadwood) and lengthy disruption to the business.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Alcon merger agreement or cause the consummation of the proposed transaction to be delayed or fail to occur.
• The failure to obtain approval of the proposed transaction from STAAR's stockholders.
• The failure to obtain certain required regulatory approvals or to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with its customers, suppliers, and others with whom it does business, or on its operating results and business generally.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• Overweight exposure to China, where growth has slowed, and macroeconomic conditions, new market entrants, and the resulting potential for pricing pressure are creating greater risks and headwinds.
• STAAR's limited product offering, deriving nearly all of its Net Sales from EVO and EVO+ ICLs, creates a heightened risk profile for the company.
• Historical inability to penetrate the market beyond high myopia patients, despite the broader applicability of EVO ICLs.
• Mediumand long-term global tariff risk still exists, especially in an unpredictable geopolitical environment, despite short-term mitigation efforts through consignment inventory and Switzerland manufacturing.
• Increasing competition in China is expected to drive downward pricing pressure and could lead to the introduction of volume-based procurement (VBP), which will be difficult to navigate with STAAR's limited product offering.

Future Outlook

STAAR management projects a significantly lower go-forward growth profile, with 2026 Net Sales estimated at $340 million, representing a 2% CAGR from 2023. China Net Sales are projected to decline in FY2025E and remain flat compared to 2024 by 2026, down significantly from 2023. The company does not expect to be profitable for FY2025. If the Alcon merger is not approved, STAAR expects its valuation would face considerable downward pressure due to ongoing standalone risks, intensifying competition, and a lack of return to historical growth rates or profitability.

Management Comments

• "We have talked with many STAAR stockholders and analysts over the past weeks who are supportive of the Alcon merger and recognize the compelling value it provides, which is why we are confident that the majority of our stockholders will vote FOR the Alcon merger." Stephen Farrell, CEO of STAAR.
• "Broadwood has a fundamentally different view of the Company’s growth trajectory that is based on assumptions that are not just aggressive, they are unachievable." Stephen Farrell, CEO of STAAR.
• "Management is working hard and expects to be successful in reversing the multi-year trend of declining Net Sales, yet we expect our future long-term growth rate will be dramatically lower than what STAAR achieved in the 2020 to 2023 time period." Stephen Farrell, CEO of STAAR.
• "STAAR is a single product company serving a narrow portion of an increasingly competitive market that has experienced demand challenges for several years in its largest market; STAAR needs a partner like Alcon to broaden its portfolio and better address its rapidly evolving risks." Stephen Farrell, CEO of STAAR.
• "If the Alcon merger does not move forward, we believe STAAR’s valuation will fall substantially, exposing stockholders to significant risk." Stephen Farrell, CEO of STAAR.
• "As a significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide." STAAR CEO.

Industry Context

The ophthalmic industry, particularly the refractive surgery segment, is highly competitive, with large global players offering various treatment options such as LASIK, SMILE, PRK, and phakic IOLs. While the total addressable market for myopia is substantial (2.2 billion potential procedures), only a small fraction (5.2 million projected in 2025) undergo refractive surgery, with laser vision correction (LVC) accounting for the majority. STAAR's Implantable Collamer Lenses (ICLs) primarily target high myopia patients, a smaller segment, and face challenges in expanding to moderate/low myopia. The China market, which constitutes over 50% of STAAR's sales, is experiencing macroeconomic headwinds, subdued consumer confidence, and increasing local competition. This includes new market entrants and the potential for volume-based procurement (VBP), which could lead to significant pricing pressure and impact STAAR's profitability and market share.

Comparison to Industry Standards

• The $28.00 per share all-cash offer represents a 59% premium to STAAR's 90-day VWAP, which is significantly higher than the median premium paid of 26% in comparable U.S. cash-only MedTech deals over $500 million announced since 2015.
• Broadwood Partners' valuation analysis is considered flawed because its selected peer set has a median 2024-2027E Net Sales CAGR of 19%, whereas STAAR's projected CAGR is 6%, making the companies not comparable. STAAR ranks last (15 out of 15) in growth among Broadwood's chosen peers.
• Alcon's substantial resources, including a sales force of 3,900 compared to STAAR's 215, R&D spend of $876 million compared to STAAR's $54 million, and sales/marketing spend of $2,553 million compared to STAAR's $108 million, position Alcon significantly better to accelerate ICL adoption and navigate competitive pressures, especially if volume-based procurement (VBP) is implemented in China.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive a significant premium and immediate cash value, de-risking their investment. There is a risk of significant stock price decline if the merger fails.
• Employees: Equity awards will be cashed out, applying equally to all employees. There is potential for disruption to management's attention due to the transaction.
• Customers/Surgeons/Patients: Alcon's greater resources are expected to accelerate EVO ICL adoption, potentially benefiting more patients worldwide.
• Suppliers/Distributors: Potential impact on relationships due to the merger announcement and integration process.

Next Steps

• STAAR stockholders are urged to thoroughly read all relevant documents filed or to be filed with the SEC, including the Proxy Statement.
• STAAR stockholders are urged to vote FOR the Alcon merger on the WHITE proxy card.
• STAAR intends to pre-release 3Q25 Net Sales after the quarter end.
• Alcon expects the deal to close within 6-12 months from the announcement date of August 5, 2025.

Key Dates

Recommendation

The filing presents a compelling case for the Alcon merger, offering STAAR stockholders a substantial 59% premium over the 90-day VWAP and immediate cash value. This de-risks investment in a company facing significant standalone challenges, including declining Net Sales, unprofitability, intense competition, and macroeconomic headwinds in its largest market (China). The Board's extensive evaluation, favorable negotiated terms, and the absence of competing offers during the window shop period strongly suggest this is the best available outcome for stockholders. Voting against the merger would expose stockholders to considerable downside risk and a likely significant decline in stock price.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Ophthalmology, Implantable Collamer Lenses, EVO ICL, Vision Correction, SEC Filing, 8-K, Proxy Solicitation, Shareholder Vote, MedTech, China Market, Myopia, Refractive Surgery, Corporate Governance, Broadwood Partners